Pavlak Marina, Stojković Ranko, Radacić-Aumiler Matea, Kasnar-Samprec Jelena, Jercić Jure, Vlahović Ksenija, Zinić Biserka, Radacić Marko
Department of Biology, Faculty of Veterinary Medicine, Zagreb University, Heinzelova 55, 10000, Zagreb, Croatia.
J Cancer Res Clin Oncol. 2005 Dec;131(12):829-36. doi: 10.1007/s00432-005-0026-z. Epub 2005 Nov 15.
The purpose of this study was to investigate in vivo antitumor activity of newly synthesized N-sulfonylpyrimidine derivatives 1-(p-toluenesulfonyl)cytosine (4H), 1-(p-toluenesulfonyl)cytosine hydrochloride (4HxHCl) and zinc(II) complex of 1-(p-toluenesulfonyl)cytosine (4K).
In order to do that we have used mouse anaplastic mammary carcinoma (AMCa). Tumor cells (10(6)) in a volume of 0.02 ml were transplanted into the thigh of the right hind leg of CBA mice. All compounds were dissolved in distilled water immediately before injecting to animals.
Antitumor effect of these compounds depends on drug doses and time interval between tumor transplantation and drug application. Further the efficacy of these compounds depends on number of drug injections, i. e. whether drug was given in single or in multiple doses. Multiple doses of 400 mg/kg of 1-(p-toluenesulfonyl)cytosine (4H) showed good antitumor effect when applied on day 1, 3, 5, 7 and 9 after tumor transplantation. Still good but slightly lower antitumor effect was also achieved when that compound was given in a single dose (1,200 mg/kg) on day 1 after tumor transplantation. The longest period of tumor growth time was obtained after application of 1-(p-toluenesulfonyl)cytosine hydrochloride (4HxHCl) given as a single dose (300 mg/kg) on day 1 or on day 6 after tumor implantation. However, antitumor effect of zinc(II) complex of 1-(p-toluenesulfonyl)cytosine (4K) was very strong when 300 mg/kg was given on day 1 or day 6, while this effect was slightly lower when drug (200 mg/kg/inj) was given on day 1, 3, 5, 7 and 9 or on day 6, 8, 10, 12 and 14.
In this work it has been found that N-1-sulfonylcytosine derivatives have strong antitumor activity against mouse mammary carcinoma which is a good reason for further research of these compounds both in experimental and preclinical studies.
本研究旨在调查新合成的N-磺酰基嘧啶衍生物1-(对甲苯磺酰基)胞嘧啶(4H)、1-(对甲苯磺酰基)胞嘧啶盐酸盐(4HxHCl)和1-(对甲苯磺酰基)胞嘧啶锌(II)配合物(4K)的体内抗肿瘤活性。
为了进行此项研究,我们使用了小鼠间变性乳腺癌(AMCa)。将体积为0.02 ml的肿瘤细胞(10⁶个)移植到CBA小鼠右后腿的大腿中。所有化合物在注射给动物之前立即溶解于蒸馏水中。
这些化合物的抗肿瘤作用取决于药物剂量以及肿瘤移植与药物应用之间的时间间隔。此外,这些化合物的疗效还取决于药物注射次数,即药物是单次给药还是多次给药。在肿瘤移植后的第1、3、5、7和9天应用多次剂量的400 mg/kg的1-(对甲苯磺酰基)胞嘧啶(4H)显示出良好的抗肿瘤效果。当该化合物在肿瘤移植后的第1天单次给药(1200 mg/kg)时,也获得了良好但略低的抗肿瘤效果。在肿瘤植入后的第1天或第6天单次给药(300 mg/kg)的1-(对甲苯磺酰基)胞嘧啶盐酸盐(4HxHCl)后,获得了最长的肿瘤生长时间。然而,当在第1天或第6天给予300 mg/kg的1-(对甲苯磺酰基)胞嘧啶锌(II)配合物(4K)时,其抗肿瘤作用非常强,而当在第1、3、5、7和9天或第6、8、10、12和14天给予药物(200 mg/kg/次注射)时,这种作用略低。
在这项工作中发现,N-1-磺酰基胞嘧啶衍生物对小鼠乳腺癌具有很强的抗肿瘤活性,这是在实验和临床前研究中进一步研究这些化合物的充分理由。